

Ghaith Abu-Zeinah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3296412/publications.pdf>

Version: 2024-02-01

22
papers

406
citations

1307594

7
h-index

839539

18
g-index

24
all docs

24
docs citations

24
times ranked

757
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. <i>Nature</i> , 2019, 571, 355-360.	27.8	206
2	Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. <i>Leukemia</i> , 2021, 35, 2592-2601.	7.2	52
3	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 50-58.	4.9	41
4	<p>Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options</p>. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 305-318.	1.7	23
5	Normal life expectancy for polycythemia vera (PV) patients is possible. <i>Leukemia</i> , 2022, 36, 569-572.	7.2	16
6	Megakaryocyte TGFβ ²¹ partitions erythropoiesis into immature progenitor/stem cells and maturing precursors. <i>Blood</i> , 2020, 136, 1044-1054.	1.4	11
7	Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 233-239.	2.1	10
8	Acute myeloid leukemia masquerading as hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, E31-E35.	1.4	6
9	Excess Mortality in Young Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2021, 138, 235-235.	1.4	6
10	Excess mortality in younger patients with myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2023, 64, 725-729.	1.3	5
11	Outcomes in <sc>CLL</sc> patients with <sc><i>NOTCH1</i></sc> regulatory pathway mutations. <i>American Journal of Hematology</i> , 2021, 96, E187-E189.	4.1	4
12	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. <i>Blood</i> , 2020, 136, 31-32.	1.4	4
13	Hematopoietic fitness of <i>JAK2V617F</i> myeloproliferative neoplasms is linked to clinical outcome. <i>Blood Advances</i> , 2022, 6, 5477-5481.	5.2	4
14	Myeloproliferative Neoplasm (MPN) Driver Mutations Are Enriched during Hematopoietic Stem Cell Differentiation in Patterns That Correlate with Clinical Phenotype and Treatment Response. <i>Blood</i> , 2018, 132, 4317-4317.	1.4	2
15	From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 103-7.	0.7	2
16	A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients. <i>Blood</i> , 2021, 138, 3619-3619.	1.4	2
17	Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-4.	0.3	1
18	Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for <i>JAK2 V617F</i> Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2021, 138, 627-627.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Normal Life Expectancy for Polycythemia Vera Patients Is Possible. <i>Blood</i> , 2021, 138, 2575-2575.	1.4	1
20	Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics. <i>Blood</i> , 2021, 138, 2583-2583.	1.4	1
21	Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFN α) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis. <i>Blood</i> , 2018, 132, 4316-4316.	1.4	0
22	Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival. <i>Blood</i> , 2021, 138, 2580-2580.	1.4	0